查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2151502

自體幹細胞和非幹細胞療法市場規模、佔有率和趨勢分析報告：按類型、應用、最終用戶、地區和細分市場預測（2026-2033 年）

Autologous Stem Cell & Non-stem Cell Therapies Market Size, Share & Trends Analysis Report By Type, By Application, By End User, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

自體幹細胞和非幹細胞治療市場概述

預計到 2025 年，全球自體和非幹細胞療法市場價值將達到 63 億美元，到 2026 年將成長至 71 億美元，到 2033 年將擴大至 175 億美元，2026 年至 2033 年的複合年成長率為 13.8%。

北美市場處於領先地位，預計到 2025 年將佔全球銷售額的 41.3%。市場成長的促進因素包括個人化醫療的日益普及、慢性病盛行率的上升以及細胞處理、製造和治療應用方面的技術進步。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 產業分析工具

第4章：按類型進行業務分析

  • 自體幹細胞和非幹細胞療法市場：按類型分類的趨勢分析
  • 自體體幹細胞
  • 自體非幹細胞

第5章：按應用程式進行業務分析

  • 自體幹細胞和非幹細胞療法市場：按應用分類的趨勢分析
  • 癌症
  • 神經退化性疾病
  • 心血管疾病
  • 整形外科疾病
  • 其他用途

第6章：最終用戶業務分析

  • 自體幹細胞和非幹細胞療法市場：終端用戶趨勢分析
  • 醫院
  • 門診手術中心
  • 研究設施

第7章 區域業務分析

  • 自體幹細胞和非幹細胞療法的市場佔有率：按地區分類，2025 年和 2033 年
  • 北美洲
    • 2021-2033年北美自體與非幹細胞療法市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲自體與非幹細胞療法市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區自體與非幹細胞療法市場
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 2021-2033年拉丁美洲自體與非幹細胞療法市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2021-2033年中東及非洲自體及非幹細胞療法市場
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 公司分類
  • 企業市場占有率及定位分析，2025年
  • 策略規劃
  • 公司簡介列表
    • Kite Pharma（acquired by Gilead Sciences, Inc.）
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Janssen Pharmaceuticals, Inc.（a subsidiary of Johnson & Johnson）
    • Vericel
    • IOVANCE Biotherapeutics, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • PHARMICELL Co., Ltd
    • GC Cell
    • ImmunoACT
    • Tegoscience
    • Anterogen Co., Ltd.
Product Code: GVR-4-68041-037-9

Autologous Stem Cell & Non-stem Cell Therapies Market Summary

The global autologous stem cell & non-stem cell therapies market size was valued at USD 6.3 billion in 2025 and is projected to grow from USD 7.1 billion in 2026 to USD 17.5 billion by 2033, at a CAGR of 13.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.3% in 2025. Market growth is driven by increasing adoption of personalized therapies, rising prevalence of chronic diseases, and advancements in cell processing, manufacturing, and therapeutic applications.

Global Autologous Stem Cell & Non-stem Cell Therapies Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global autologous stem cell & non-stem cell therapies market report on the basis of type, application, end user, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Autologous Stem Cells
  • Autologous Non-Stem Cells
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cancer
  • Neurodegenerative Disorders
  • Cardiovascular Disease
  • Orthopedic Diseases
  • Other Applications
  • End User Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Ambulatory Surgical Centers
  • Research Facilities
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. End User Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. List of Secondary Sources
    • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Demand for Personalized and Patient-Specific Therapies
      • 3.2.1.2. Rising Prevalence of Chronic and Degenerative Diseases
      • 3.2.1.3. Increasing Clinical Research and Pipeline of Autologous Cell Therapies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Complexity of Cell Collection, Processing, and Handling
      • 3.2.2.2. Stringent Regulatory and Quality Requirements
    • 3.2.3. Market Opportunities Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Economic landscape
      • 3.3.2.5. Legal landscape

Chapter 4. Type Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Autologous Stem Cell & Non-stem Cell Therapies Market: Type Movement Analysis
  • 4.3. Autologous Stem Cells
    • 4.3.1. Autologous Stem Cells Market, 2021 - 2033 (USD Million)
  • 4.4. Autologous Non-Stem Cells
    • 4.4.1. Autologous Non-Stem Cells Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Autologous Stem Cell & Non-stem Cell Therapies Market: Application Movement Analysis
  • 5.3. Cancer
    • 5.3.1. Cancer Market, 2021 - 2033 (USD Million)
  • 5.4. Neurodegenerative Disorders
    • 5.4.1. Neurodegenerative Disorders Market, 2021 - 2033 (USD Million)
  • 5.5. Cardiovascular Disease
    • 5.5.1. Cardiovascular Disease Market, 2021 - 2033 (USD Million)
  • 5.6. Orthopedic Diseases
    • 5.6.1. Orthopedic Diseases Market, 2021 - 2033 (USD Million)
  • 5.7. Other Applications
    • 5.7.1. Other Applications Market, 2021 - 2033 (USD Million)

Chapter 6. End User Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Autologous Stem Cell & Non-stem Cell Therapies Market: End User Movement Analysis
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 6.5. Research Facilities
    • 6.5.1. Research Facilities Market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Autologous Stem Cell & Non-stem Cell Therapies Market Share By Region, 2025 & 2033
  • 7.2. North America
    • 7.2.1. North America Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Competitive Scenario
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Mexico Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. UK Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Germany Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. France Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Italy Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Spain Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Denmark Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Sweden Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Norway Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. India Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Australia Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Thailand Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. South Korea Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Brazil Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Argentina Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. South Africa Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. UAE Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Kuwait Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Share/ Position Analysis, 2025
  • 8.3. Strategy Mapping
  • 8.4. Company Profiles/Listing
    • 8.4.1. Kite Pharma (acquired by Gilead Sciences, Inc.)
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Bristol-Myers Squibb Company
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Novartis AG
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson)
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Vericel
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. IOVANCE Biotherapeutics, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. PHARMICELL Co., Ltd
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. GC Cell
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. ImmunoACT
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
    • 8.4.11. Tegoscience
      • 8.4.11.1. Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Strategic Initiatives
    • 8.4.12. Anterogen Co., Ltd.
      • 8.4.12.1. Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 4 Global autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 5 Global autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 6 Global autologous stem cell and non-stem cell therapies market, by region, 2021 - 2033 (USD Million)
  • Table 7 North America autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 9 North America autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 10 North America autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 11 U.S. autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 12 U.S. autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 13 U.S. autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 14 Canada autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 15 Canada autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 16 Canada autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 17 Mexico autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 18 Mexico autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 19 Mexico autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 20 Europe autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 22 Europe autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 23 Europe autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 24 UK autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 25 UK autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 26 UK autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 27 Germany autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 28 Germany autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 29 Germany autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 30 France autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 31 France autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 32 France autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 33 Italy autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 34 Italy autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 35 Italy autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 36 Spain autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 37 Spain autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 38 Spain autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 39 Denmark autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 40 Denmark autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 41 Denmark autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 42 Sweden autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 43 Sweden autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 44 Sweden autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 45 Norway autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 46 Norway autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 47 Norway autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 52 Japan autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 53 Japan autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 54 Japan autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 55 China autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 56 China autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 57 China autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 58 India autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 59 India autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 60 India autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 61 Australia autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 62 Australia autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 63 Australia autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 64 Thailand autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 65 Thailand autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 66 Thailand autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 67 South Korea autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 68 South Korea autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 69 South Korea autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 70 Latin America autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 72 Latin America autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 73 Latin America autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 74 Brazil autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 75 Brazil autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 76 Brazil autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 77 Argentina autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 78 Argentina autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 79 Argentina autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 84 South Africa autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 85 South Africa autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 86 South Africa autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 90 UAE autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 91 UAE autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 92 UAE autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)
  • Table 93 Kuwait autologous stem cell and non-stem cell therapies market, by type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait autologous stem cell and non-stem cell therapies market, by application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait autologous stem cell and non-stem cell therapies market, by end user, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Autologous stem cell and non-stem cell therapies market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Autologous stem cell and non-stem cell therapies market driver analysis
  • Fig. 12 Autologous stem cell and non-stem cell therapies market restraint analysis
  • Fig. 13 Autologous stem cell and non-stem cell therapies market: Porter's five forces analysis
  • Fig. 14 Autologous stem cell and non-stem cell therapies market: PESTLE analysis
  • Fig. 15 Autologous stem cell and non-stem cell therapies market: type outlook and key takeaways
  • Fig. 16 Autologous stem cell and non-stem cell therapies market: type market share analysis
  • Fig. 17 Autologous stem cells market, 2021 - 2033 (USD Million)
  • Fig. 18 Autologous non-stem cells market, 2021 - 2033 (USD Million)
  • Fig. 19 Autologous stem cell and non-stem cell therapies market: application outlook and key takeaways
  • Fig. 20 Autologous stem cell and non-stem cell therapies market: application market share analysis
  • Fig. 21 Cancer market, 2021 - 2033 (USD Million)
  • Fig. 22 Neurodegenerative disorders market, 2021 - 2033 (USD Million)
  • Fig. 23 Cardiovascular disease market, 2021 - 2033 (USD Million)
  • Fig. 24 Orthopedic diseases market, 2021 - 2033 (USD Million)
  • Fig. 25 Other applications market, 2021 - 2033 (USD Million)
  • Fig. 26 Autologous stem cell and non-stem cell therapies market: end user outlook and key takeaways
  • Fig. 27 Autologous stem cell and non-stem cell therapies market: end user market share analysis
  • Fig. 28 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 29 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 30 Research facilities market, 2021 - 2033 (USD Million)
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Fig. 37 UK autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 39 France autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 42 Denmark autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 45 Asia Pacific autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Fig. 46 Japan autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 47 China autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 48 India autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 49 Australia autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 50 Thailand autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 51 South Korea autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 52 Latin America autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Fig. 53 Brazil autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 54 Argentina autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 55 MEA autologous stem cell and non-stem cell therapies market, by country, 2021 - 2033 (USD Million)
  • Fig. 56 South Africa autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 57 Saudi Arabia autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 58 UAE autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)
  • Fig. 59 Kuwait autologous stem cell and non-stem cell therapies market, 2021 - 2033 (USD Million)